PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS
| Autor: | Carrasco Perez, M., Ustyugova, A., Rubio, M., Callejo-Velasco, D., Gasche, D., Gonzalez-Rojas Guix, N. |
|---|---|
| Zdroj: | In Value in Health November 2019 22 Supplement 3:S575-S575 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect